Prestige BioPharma Limited
KSE:950210.KS
14760 (KRW) • At close July 31, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,339.945 | 3,114.81 | 2,221.648 | -137.09 | 643.028 | 119.894 | 67.323 | 161.056 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 572.292 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 13,140.517 | 18,704.125 | 0 | 1,217.868 | 4,478.792 | 3,841.792 | 3,414.928 | 3,415.647 | 3,263.992 | 3,146.931 | 1,800.186 | 228.95 | 955.456 | 964.046 | 0 | 530.443 | 0 | 0 | 0 | 0 | 5.488 |
| Gross Profit
| -9,682.038 | -15,589.315 | 2,221.648 | -1,354.958 | -3,835.764 | -3,721.899 | -3,347.493 | -3,254.591 | -3,263.992 | -3,146.931 | -1,800.186 | -1,181.812 | -955.456 | -964.046 | -782.583 | -530.443 | 572.292 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| -2.899 | -5.005 | 1 | 9.884 | -5.965 | -31.043 | -49.723 | -20.208 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 6,208.739 | 0 | 5,137.086 | 0 | 7,762.919 | 11,906.233 | 8,137.26 | 11,159.023 | 13,292 | 11,070.163 | 5,203.462 | 333.76 | 9,401.192 | 5,388.611 | 2,456.73 | 0 | 5,249.614 | 0 | 0 | 0 | 886.794 |
| General & Administrative Expenses
| 18,686.094 | 24,449.63 | 17,724.778 | 167.991 | 17,381.631 | 19,060.444 | 17,242.858 | 399.71 | 19,726.562 | 17,030.181 | 12,358.679 | -3,008.255 | 12,968.009 | 8,797.978 | 5,307.721 | 300.533 | 9,152.329 | 2,900.622 | 2,490.828 | 450.332 | 84.028 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 12,694.298 | -12,121.808 | -15,665.156 | 0 | 0 | 0 | 0 | 0 | 18,587.431 | 0 | 0 | 0 | 7,517.365 | 0 | 0 | 0 | 3,808.104 | 286.224 |
| SG&A
| 18,686.094 | 24,449.63 | 17,724.778 | -23,965.589 | 5,259.823 | 3,395.288 | 17,242.858 | -9,089.753 | 19,726.562 | 17,030.181 | 12,358.679 | 15,579.176 | 12,968.009 | 8,797.978 | 5,307.721 | 7,817.898 | 9,152.329 | 2,900.622 | 2,490.828 | 7,042.257 | 370.252 |
| Other Expenses
| 0 | 0 | -0.001 | 33,572.831 | 0 | 0 | 0.001 | 18,682.84 | -1,212.317 | -14,052.544 | 70,516.66 | 15,670.177 | -72,559.935 | -4,829.709 | 0 | -3,845.683 | -4,800.816 | 3,091.369 | 1,473.031 | -1,127.15 | 1,236.129 |
| Operating Expenses
| 6,208.739 | 24,449.63 | 17,968.995 | 8,422.554 | 13,022.742 | 15,301.521 | 13,856.769 | 20,885.712 | 19,726.562 | 20,122.95 | 10,586.026 | 31,249.353 | 12,968.009 | 7,931.371 | 4,533.716 | 3,452.344 | 9,724.621 | 2,841.752 | 2,417.709 | 3,017.208 | 2,493.174 |
| Operating Income
| -15,346.149 | -21,334.82 | -15,503.129 | -9,744.332 | -16,743.008 | -18,941.069 | -17,175.536 | -20,885.712 | -19,726.562 | -17,030.181 | -12,358.679 | -31,249.354 | -12,968.009 | -8,797.978 | -5,307.721 | -3,972.215 | -9,152.329 | -2,900.622 | -2,490.828 | -3,017.208 | -2,493.175 |
| Operating Income Ratio
| -4.595 | -6.849 | -6.978 | 71.08 | -26.038 | -157.982 | -255.121 | -129.68 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15.992 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 61,541.528 | -263.632 | 4,925.001 | -3,154.347 | 3,591.268 | 7,348.346 | 283.087 | 5,681.442 | -1,382.163 | -2,401.934 | 66,202.454 | -69,922.365 | -72,363.403 | -4,837.796 | -4,862.941 | 6,618.796 | -1,024.78 | 3,030.145 | 2,090.156 | -4,013.226 | -155.569 |
| Income Before Tax
| 46,195.379 | -21,598.452 | -10,645.066 | -12,898.679 | -13,151.74 | -11,592.723 | -16,892.449 | -15,204.27 | -21,108.725 | -19,432.115 | 53,843.775 | -101,171.719 | -85,331.412 | -13,635.774 | -10,170.662 | 2,646.581 | -10,177.109 | 129.523 | -400.672 | -7,030.434 | -2,648.744 |
| Income Before Tax Ratio
| 13.831 | -6.934 | -4.792 | 94.089 | -20.453 | -96.691 | -250.916 | -94.404 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -17.783 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -1.478 | -167.268 | 148.465 | 157.145 | 145.26 | -33.494 | 139.756 | 128.841 | 411.627 | 9.207 | 215.938 | 138.07 | 399.585 | 260.561 | 0 | -0.149 | 28.522 | 5.768 | -0.047 | 0.762 | 0 |
| Net Income
| 50,462.172 | -13,185.845 | -5,784.919 | -9,285.173 | -1,437.872 | -12,971.581 | -9,122.322 | -8,806.926 | -14,353.368 | -18,278.442 | 59,277.404 | -101,309.789 | -85,730.996 | -13,896.335 | -10,187.099 | 2,646.73 | -10,205.632 | 119.943 | -400.373 | -7,031.196 | -2,648.744 |
| Net Income Ratio
| 15.109 | -4.233 | -2.604 | 67.73 | -2.236 | -108.192 | -135.501 | -54.682 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -17.833 | 0 | 0 | 0 | 0 |
| EPS
| 838.4 | -223.2 | -95.2 | -154.51 | -23.8 | -216.79 | -152 | -146.55 | -238.84 | -304.8 | 987.4 | -1,684.69 | -1,427.2 | -231.8 | -169.24 | 44.04 | -210 | 2.4 | -9.6 | -157.27 | -64 |
| EPS Diluted
| 838.4 | -223.2 | -95.2 | -154.51 | -23.8 | -215.8 | -152 | -146.55 | -238.4 | -304.8 | 987.4 | -1,684.69 | -1,427.2 | -231.8 | -169 | 44.04 | -210 | 2.4 | -9.6 | -157.27 | -64 |
| EBITDA
| -15,346.149 | -21,334.82 | -15,503.13 | 5,753.39 | -16,743.008 | -18,941.069 | -15,055.959 | 47,542.291 | -19,726.562 | -17,030.181 | 53,984.71 | -183,363.738 | -12,968.009 | -8,797.978 | -5,307.721 | 3,105.467 | -9,152.329 | -2,900.622 | -2,490.828 | -2,465.15 | -2,438.183 |
| EBITDA Ratio
| -4.595 | -6.849 | -6.978 | -41.968 | -26.038 | -157.982 | -223.638 | 295.191 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15.992 | 0 | 0 | 0 | 0 |